17:00 , Aug 3, 2018 |  BC Week In Review  |  Clinical News

Takeda's subcutaneous Entyvio meets in Phase III for maintenance therapy of ulcerative colitis

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said subcutaneous Entyvio vedolizumab as maintenance therapy met the primary endpoint vs. placebo in the Phase III VISIBLE 1 trial to treat ulcerative colitis in patients who achieved a clinical...
23:16 , Jul 20, 2018 |  BC Extra  |  Preclinical News

PI3K inhibitors may block cancer's access to CNS

Researchers from Duke University, Gilead Sciences Inc. (NASDAQ:GILD) and colleagues suggested that acute lymphoblastic leukemia (ALL) cells metastasize to the CNS by traveling along vessels rich in laminin, a protein associated with motility of neuronal...
16:35 , Jul 20, 2018 |  BC Week In Review  |  Financial News

Fibrotic disease company Pliant raises $62M series B

Fibrosis play Pliant Therapeutics Inc. (Redwood City, Calif.) raised $62 million on July 16 in an untranched series B round led by Cowen Healthcare Investments. Fellow new investors Eventide Asset Management, Schroder Adveq, Menlo Ventures,...
17:45 , Jul 18, 2018 |  BioCentury  |  Finance

Fibrosis firsts

Pliant Therapeutics Inc.’s preclinical models and discovery technology prompted Cowen Healthcare Investments and Menlo Ventures to choose the company as their first fibrosis investments. Cowen led Pliant’s untranched $62 million series B round on Monday, joined...
17:33 , Jul 17, 2018 |  BC Innovations  |  Distillery Therapeutics

Dermatology

INDICATION: Dermal ulcers Mouse studies suggest a laminin peptide-antioxidant conjugate could help treat diabetic foot ulcers. The conjugate consists of a 12-mer peptide derived from LAMA5, which interacts with CD49C/CD29 and other integrins to promote...
21:06 , May 16, 2018 |  BC Extra  |  Preclinical News

Nanoparticle pretreatment could boost solid tumor CAR T therapy

Research from the University of Washington and the Fred Hutchinson Cancer Research Center suggests preconditioning cancer patients with immunomodulatory nanoparticles could increase the efficacy of CAR T therapies to treat solid tumors. The main hypothesis as...
17:56 , Mar 30, 2018 |  BC Week In Review  |  Clinical News

Protagonist discontinues Phase IIb of PTG-100 for UC

Protagonist Therapeutics Inc. (NASDAQ:PTGX) discontinued the Phase IIb PROPEL trial of once-daily PTG-100 to treat moderate to severe ulcerative colitis. Protagonist said it will decide whether to start a Phase II/III trial of the candidate...
18:13 , Mar 26, 2018 |  BC Extra  |  Clinical News

Protagonist shares halved on UC failure

Protagonist Therapeutics Inc. (NASDAQ:PTGX) was down $11.68 (57%) to $8.75 on Monday after the company discontinued the Phase IIb PROPEL trial of PTG-100 to treat moderate to severe ulcerative colitis. Protagonist said it will decide...
17:49 , Mar 13, 2018 |  BC Innovations  |  Distillery Techniques

Drug delivery

TECHNOLOGY: Nanoparticles Photothermal-activated, tumor-targeted nanoparticles could be used to deliver cancer therapies. The nanoparticles consist of β-cyclodextrin-based polyrotaxane and the photothermal agent perylene diimide to enable release of drug cargo in response to near-infrared (NIR) laser...
19:18 , Feb 21, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Plasma markers The pre-HIV infection fraction of CD4+ T cells expressing integrin α4β7 could help predict susceptibility to HIV infection. In 70 of 206 at-risk women from South Africa and Kenya who contracted HIV via...